Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.5052W HIGH $62.40
Volume
372.65 K
Value Traded
218.04 K
Short % Float
1.35%
Days to Cover
1.0
-9.31%Week
-57.28%1 Month
-81.96%3 Month
-91.62%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
936.11 K
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
1.65 M
Float Shares
1.08 M
Insiders
34.40%
Institutions
0.63%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
IMCC Catalyst Timeline
Dated clinical, regulatory and corporate events for IM Cannabis Corp.
Catalyst Timeline
Dated clinical, regulatory & corporate events for IM Cannabis Corp.
236Total events
5Upcoming
62Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Debt Royalty FinancingCorporate
Closed US$1,200,000 convertible note financing with existing institutional investor
▲AcquiredCorporate
Closing of sale of IMC Holdings and European-focused operations to Slil.com Holding Ltd.
▼Equity OfferingCorporate
Closing of US$1.31 million registered direct offering of 655,000 common shares at US$2.00 per share
●Partnership / LicenseCorporate
Invest-Pro subscribed for 164,585 common shares in the offering
●Corporate ApprovalCorporate
Independent directors approved the Offering and reliance on MI 61-101 exemptions
▲Other Regulator MilestoneEx-US Regulatory
IM Cannabis regains compliance with Nasdaq minimum bid price requirement
▼Equity OfferingCorporate
Pricing of US$1.31 million registered direct offering of 655,000 common shares at US$2.00 per share
▲AcquisitionCorporate
IMCC enters non-binding LOI to acquire 51% of Space Defense Innovations LLC
◆Timing GuidancePresentation
Completion of pending transactions expected; German operations to be sold, Israeli operations retained
◆AcquisitionCorporate
IM Cannabis enters into definitive share purchase agreement to sell IMC Holdings to Slil
▼Equity OfferingCorporate
Resale registration statement filed for up to 17,276,931 common shares
▼Equity OfferingCorporate
Closed US$225,000 convertible note financing with institutional investor
▲Quarterly UpdateCorporate
Reported 2025 full-year results with revenue of C$54.7 million and positive operating cash flow
◆Timing GuidancePresentation
Deadline to regain compliance with Nasdaq Stockholders' Equity Requirement
▲FDA Feedback ReceivedFDA Meeting
Regained compliance with Nasdaq stockholders' equity listing requirement
◆Equity OfferingCorporate
Best efforts to raise at least USD 3 million via underwritten offering with Aegis Capital Corp.
▼Equity OfferingCorporate
Closed private placement for gross proceeds of approximately US$4.1 million
◆ATM ProgramCorporate
Filing of shelf registration statement on Form F-3 for up to $50 million
◆Debt Royalty FinancingCorporate
Loan Agreement with L.I.A. Pure Capital Ltd. for up to USD 2 million
▲FDA Filing AcceptedRegulatory Filing
Nasdaq granted extension to regain compliance until October 6, 2025
▼Equity OfferingCorporate
Exercise of 152,701 Pre-Funded Warrants by Oren Shuster effective May 26, 2025
●Timing GuidancePresentation
Submitted compliance plan to Nasdaq to regain compliance with Listing Rule 5550(b)(1)
◆Quarterly UpdateCorporate
Annual general and special meeting of shareholders to vote on Focus Transaction
◆AcquisitionCorporate
Plan to acquire remaining 26% interest in Focus Medical Herbs Ltd. from Ewave Group Ltd.
Past FDA Catalysts and PDUFA Decisions
How IMCC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
IM Cannabis Corp. is not a drug developer. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every IMCC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in IMCC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in IMCC for Q2 2026. | ||||
Ownership Trends
IMCC Short Interest
Shares sold short, counted twice a month.
1.35%
Short % of Float
of tradable shares sold short
14.6K
Shares Sold Short
-59.6% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
73.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IMCC ranks across every disease it competes in
Competitive Position is a premium feature
See how IMCC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIMCC News
-IMCC
Nov 13, 2026▲ +2.8%today
IM Cannabis Corp. Announces Third Quarter 2026 Financial Results
IM Cannabis Corp. reported disappointing financial results for Q3 2026, with revenue dropping to C$1.65 million from C$5.08 million a year earlier. The net loss also widened to C$7.08 million compared to C$3.87 million in Q3 2025. The company is pursuing a strategic acquisition while restructuring its operations.
Read more →-IMCC
Nov 4, 2026▼ -17.2%on this news
IM Cannabis Raises US$1,200,000 of Gross Proceeds in Convertible Note Financing
IM Cannabis Corp. closed a US$1,200,000 convertible note financing with an institutional investor. The note has a 4% interest rate, maturing in 28 months, and allows conversion into common shares. Proceeds will be used for general corporate purposes, with additional financing options available starting January 2027.
Read more →-IMCC
Sep 29, 2026IM Cannabis Announces Closing of the Sale of IMC Holdings and Its European-Focused Operations, Strengthens Balance Sheet
IM Cannabis Corp. has successfully completed the sale of IMC Holdings to Slil.com Holding Ltd., which is anticipated to enhance shareholders' equity by approximately C$3 million. The transaction aims to streamline the company's structure and reduce liabilities while allowing IM Cannabis to concentrate on its Israeli medical cannabis operations. The deal involved a related party transaction due to the CEO's ownership in Slil.
Read more →-IMCC
Sep 24, 2026▼ -10.7%on this news· ran to -29% by day 3shared move
IM Cannabis Announces Closing of US$1.31 Million Registered Direct Offering of Common Shares
IM Cannabis Corp. has successfully closed a registered direct offering, raising $1.31 million by selling 655,000 common shares at $2.00 each. The funds will support working capital and explore additional business opportunities. The offering involved a related party transaction, which was approved under exemptions due to the company's financial difficulties.
Read more →-IMCC
Sep 23, 2026▲ +9.3%on this newsshared move
IM Cannabis Regains Compliance with Nasdaq Minimum Bid Price Requirement
IM Cannabis Corp. has successfully regained compliance with Nasdaq's minimum bid price requirement, as confirmed by Nasdaq's written notice. The company maintained a closing bid price of $1.00 or higher for 18 consecutive business days. This compliance resolves the previous bid price deficiency issue, allowing IMCC to continue its operations without regulatory concerns.
Read more →-IMCC
Sep 23, 2026▼ -29.7%on this news· ran to -40% by day 3shared move
IM Cannabis Announces Pricing of US$1.31 Million Registered Direct Offering of Common Shares
IM Cannabis Corp. announced a registered direct offering of 655,000 common shares at US$2.00 per share, aiming to raise approximately US$1.31 million. The proceeds will be utilized for working capital and evaluating new business opportunities. The offering is subject to customary closing conditions and may involve related party transactions.
Read more →-IMCC
Sep 23, 2026▼ -29.7%on this news· ran to -40% by day 3shared move
IM Cannabis Enters Non-Binding Agreement to Acquire 51% of Space Defense Innovations, Operating in the European Tactical UAS Market
IM Cannabis Corp. has signed a non-binding Letter of Intent to acquire 51% of Space Defense Innovations LLC, which operates in the European unmanned aerial systems market. This move aims to diversify IMCC's business beyond its core medical cannabis operations. The acquisition includes a combination of shares and warrants, with a five-year option to acquire additional shares. However, the deal is contingent on several regulatory and corporate approvals.
Read more →-IMCC
Sep 2, 2026▼ -26.7%on this news
IM Cannabis Raises US$225,000 of Gross Proceeds in Convertible Note Financing
IM Cannabis Corp. has successfully closed a US$225,000 convertible note financing with an institutional investor. The financing includes an 8% interest rate, convertible into common shares at a set price or a percentage of market value. The company plans to use the proceeds for general corporate purposes while managing risks associated with regulatory compliance and market conditions.
Read more →-IMCC
Aug 27, 2026▼ -13.5%on this news· ran to -24% by day 3
IM Cannabis Shares Commence Trading on 30:1 Consolidated Basis
IM Cannabis Corp. has begun trading its common shares on a 30:1 consolidated basis on the Nasdaq. The company aims to improve its share price and maintain compliance with Nasdaq's listing requirements. Shareholders will receive instructions for exchanging their pre-consolidation shares. The company operates in Israel and Germany, focusing on medical cannabis.
Read more →-IMCC
Aug 18, 2026IM Cannabis Announces Intention to Complete 30:1 Share Consolidation to Support Nasdaq Minimum Bid Price Compliance
IM Cannabis Corp. has announced a 30:1 share consolidation approved by its board to comply with Nasdaq's minimum bid price requirement. The consolidation is expected to take effect on August 27, 2026, with shares trading on a post-consolidation basis. The company aims to increase its share price to regain compliance by the October 6, 2026 deadline.
Read more →-IMCC
Aug 17, 2026▼ -14%on this newsshared move
IM Cannabis Enters into Agreement to Sell IMC Holdings and European- Focused Assets
IM Cannabis Corp. has entered into a definitive share purchase agreement to sell IMC Holdings and its European-focused assets to Slil.com Holding Ltd. The transaction is expected to enhance shareholders' equity by approximately CAD$3 million and streamline the company's operations. However, it is classified as a related party transaction due to the CEO's involvement, raising potential concerns about conflicts of interest.
Read more →-IMCC
Aug 13, 2026▼ -6.1%on this news· ran to -19% by day 1shared move
IM Cannabis Corp. Announces Second Quarter and First Half 2026 Financial Results
IM Cannabis Corp. reported its financial results for Q2 and the first half of 2026, showing a significant decline in revenue and an increase in losses compared to the same periods in 2025. Revenue for the first half was $16.3 million, down from $25.2 million, while the net loss reached $6.9 million. The company's cash reserves also fell, raising concerns about financial stability.
Read more →-IMCC
Aug 7, 2026IM Cannabis Raises US$250,000 of Gross Proceeds in Convertible Note Financing
IM Cannabis Corp. has successfully closed a US$250,000 convertible note financing with an institutional investor. The financing includes an 8% interest note convertible into common shares at a set price or a percentage of market value. The company plans to use the proceeds for general corporate purposes while managing risks associated with regulatory compliance and market competition.
Read more →-IMCC
Jul 27, 2026IM Cannabis Provides Corporate Update
IM Cannabis Corp. has announced the resignation of Mr. Alon Dayan from its board of directors for personal reasons. The company expressed appreciation for his contributions during his tenure. IM Cannabis continues to focus on expanding its medical cannabis operations in Israel and Germany, while exploring new technology-driven opportunities.
Read more →-IMCC
Jun 18, 2026▼ -16.5%on this news
IM Cannabis Corp. Enters into Letter of Intent to Sell its European Activities, Expects to Significantly Reduce Debt by CAD$10.5 million
IM Cannabis Corp. has entered a non-binding letter of intent to sell its European operations to Slil.com Holding Ltd., which will significantly reduce the company's debt by CAD$10.5 million. The transaction allows IMC to concentrate on its Israeli market while pursuing new investment opportunities. The deal is subject to further negotiations and regulatory approvals.
Read more →-IMCC
Jun 9, 2026▼ -14.5%on this news
IM Cannabis Announces Form F-3 Resale Registration Statement Filing
IM Cannabis Corp. has announced the filing of a resale registration statement on Form F-3 with the SEC for 17,276,931 common shares. This registration includes shares from several convertible promissory notes, emphasizing the company's focus on managing its financial operations. While the statement has potential benefits for liquidity, it has not yet been made effective by the SEC, introducing an element of uncertainty. The company continues to operate in the medical cannabis market primarily in Israel and Germany.
Read more →-IMCC
May 13, 2026IM Cannabis Corp. Announces First Quarter 2026 Financial Results
IM Cannabis Corp. announced its financial results for Q1 2026, reporting revenues of $8.7 million but a net loss of $2.5 million. The company has made strides in cost optimization, reducing administrative expenses by 22% year-over-year. Management is focused on operational efficiencies and exploring strategic growth opportunities despite facing inherent risks in the cannabis industry.
Read more →-IMCC
May 7, 2026IM Cannabis Raised US$550,000 of Gross Proceeds in Convertible Note Financings
IM Cannabis Corp. has successfully closed a US$300,000 convertible note financing, adding to a total of US$550,000 raised in recent financings. The funds will be utilized for general corporate purposes. The company operates in Israel and Germany, focusing on medical cannabis distribution and retail. However, it faces regulatory and market challenges that could impact its future growth.
Read more →About IM Cannabis Corp.
BIOPHARMAWATCH ELITE
Trade the next IMCC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime